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Intrahepatic Extramedullary
Hematopoiesis Mimicking a
Hypervascular Hepatic Neoplasm on
Dynamic- and SPIO-Enhanced MRI
We present a rare case of a focal intrahepatic extramedullary hematopoiesis
(EMH) that mimicked a hypervascular hepatic neoplasm in a 33-year-old woman
with idiopathic myelofibrosis. The lesion showed homogeneous and persistent
enhancement on both contrast-enhanced CT and gadolinium-enhanced dynamic
MR imaging. The lesion did not demonstrate an apparent signal drop on a T2*-
weighted sequence following administration of a superparamagnetic iron-oxide
agent (SHU 555A). A hepatocellular adenoma was the initial radiological diagno-
sis. To the best of our knowledge, this is the first report of a histopathologically
proven intrahepatic EMH evaluated with dynamic- and SPIO-enhanced MRI.
xtramedullary hematopoiesis (EMH) is a compensatory mechanism by
which blood cells are produced outside the bone marrow when marrow
production is unable to maintain the needs of the organism (1). It can be
seen in a variety of hematological disorders that lack cell formation such as myelopro-
liferative diseases. EMH usually shows microscopic involvement and its most common
sites are the liver, spleen, and lymph nodes (1, 2). In rare cases, such as presented in
this report, the involvement can manifest as a mass-like lesion; this uncommon
manifestation made it difficult for us to differentiate this disease entity from other
focal hepatic neoplasms.
There have been sporadic case reports regarding the radiologic findings of focal
intrahepatic EMH (1 9). However, in most reports, only ultrasound (US) and CT
findings of this disease have been presented, and there are few reports regarding MRI
findings (5, 6, 10). Moreover, to the best of our knowledge, there have been no
reports regarding superparamagnetic iron oxide (SPIO)-enhanced MRI findings of this
disease entity. Theoretically, as EMH can possess all marrow cells, including reticu-
loendothelial system (RES) precursor cells, it can be expected that intrahepatic EMH
shows a signal drop on a T2*-weighted gradient echo sequence after SPIO administra-
tion. In addition, even though there have been a few case reports regarding the
enhancement pattern of EMH on CT, most of the reports did not address the dynamic
enhancement pattern of EMH on CT or MRI. In this case report, we present contrast-
enhanced CT as well as dynamic- and SPIO-enhanced MRI findings of a rare case of
intrahepatic EMH and correlate them with the pathology and immunohistochemistry
findings.
CASE REPORT
A 33-year-old woman with a five-year history of essential thrombocythemia, was
admitted to our hospital after the recent detection of a palpable mass in the left flank.
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EPhysical examination also revealed a palpable enlarged
spleen and liver. Laboratory findings at the time of
admission included a hemoglobin level of 14.7 g/dL, a
platelet count of 73  10
3/ l, and leukocyte count of
24,010/ l. The level of serum alpha-fetoprotein was less
than 3 ng/ml. Hepatitis serologic markers such as HBs Ag,
HCV Ab, and HAV Ab were all negative. A bone marrow
biopsy was consistent with essential thrombocythemia
transformed into idiopathic myelofibrosis.
A non-contrast CT scan showed a 2-cm sized, fairly well-
defined, and homogeneously low attenuated mass in
segment VI of the liver (data not shown). The liver and
spleen were diffusely enlarged. On contrast-enhanced,
portal venous phase CT, most of the lesion showed intense
enhancement (Fig. 1A). No other focal lesions were identi-
fied in the spleen, kidneys or paravertebral region. On
MRI, the lesion showed homogeneously low and high
signal intensity on T1- (repetition time [TR]/echo time [TE]
= 140 msec/2.4 msec, flip angle [FA] = 70 ) (Fig. 1B) and
fat-saturated T2-weighted fast spin echo images (TR/TE =
12,857.1/100.7) (Fig. 1C), respectively. There was no
signal change between the in- and opposed-phase T1-
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Fig. 1. Intrahepatic extramedullary hematopoiesis in 33-year-old woman.
A. 33-year-old woman with history of idiopathic myelofibrosis. On contrast-enhanced CT obtained in equilibrium phase, 2-cm-sized, well-
defined and homogeneously enhancing mass (arrow) is seen in segment VI of liver. Liver and spleen are diffusely enlarged.
B. Lesion (arrow) shows homogeneous low signal intensity on in-phase T1-weighted image (repetition time [TR]/echo time [TE] = 140
msec/2.4 msec, flip angle [FA] = 70 ). 
C. Lesion (arrow) shows high signal intensity on fat-saturated, T2-weighted fast spin echo image (TR/TE = 12,857.1/100.7). 
D. On serial gadolinium-BOPTA dynamic MR scans, lesion (arrows) shows homogeneous and intense enhancement on arterial phase
(20 seconds after gadolinium administration, upper right) compared with pre-contrast T1-weighted image (TR/TE = 4.7/2.2, FA = 10 )
(upper left); it enhances persistently through portal (50 seconds, lower left) to delayed phases (5 minutes, lower right). weighted images. After the administration of a dose of 0.5
mmol/kg gadolinium (Gd) (Gd-BOPTA, Multihance,
Bracco Imaging, Milan, Italy), the lesion showed homoge-
neous and intense enhancement on the arterial phase (20
seconds after contrast agent administration) and enhanced
persistently until five minutes after Gd administration (Fig.
1D). There was no signal drop in the mass on T2*-
weighted images (TR/TE = 130.0/9.7, FA = 30 ) obtained
10 minutes following the administration of 1.4 ml of an
SPIO agent (SHU 555A, Resovist, Schering AG, Germany)
(Fig. 1E).
Considering that the patient had taken an anabolic
steroid for the treatment of essential thrombocythemia and
the mass had manifested as a well-defined hypervascular
lesion, the most probable radiological diagnosis at this
point was a hepatocellular adenoma. Differential possibili-
ties also included other hypervascular hepatic neoplasms
such as a focal nodular hyperplasia (FNH), hepatocellular
carcinoma (HCC), angiomyolipoma, and a solitary
hypervascular metastasis. Although the patient did not
have any predisposing factors for HCC, a hepatic tumorec-
tomy was performed, as the possibility of a hepatic
malignancy could not be excluded. An splenectomy was
also scheduled for the symptomatic splenomegaly regard-
less of the nature of the hepatic lesion.
The patient underwent the splenectomy and segmentec-
tomy of segment VI of the liver. Grossly, a homogeneously
reddish mass without necrosis or hemorrhage was seen in
the liver. Microscopically, megakaryocytes and pleomor-
phic groups of erythroids and myeloid precursors, which
are known as the three hematological precursor cell-lines,
were seen insinuating into the hepatocyte cords (Fig. 1F).
These findings were therefore consistent with a focal
intrahepatic EMH. Even though there were some histio-
cytic cells that are usually considered as precursors of RES
cells, no Kupffer cells were found in the lesion by
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Fig. 1. Intrahepatic extramedullary hematopoiesis in 33-year-old
woman.
E. On SPIO-enhanced, T2*-weighted gradient echo image (TR/TE
= 130.0/9.7, FA = 30 ) obtained 10 minutes after SPIO administra-
tion, there is no signal drop in lesion (arrow).
F. On the photomicrograph (Hematoxylin & Eosin staining;  200),
megakaryocytes (arrow) and pleomorphic groups of erythroid and
myeloid precursors that represent three hematologic precursor cell-
lines, are seen insinuating hepatocyte cords.
G. Immunohistochemical staining using CD68 marker ( 40),
reveals that cells in extramedullary hematopoiesis are positive for
CD 68 (stained with brown color), but degree of staining in lesion
(lower part of dotted line) is much weaker than that in normal liver
(upper part of dotted line).
EF
GHematoxylin and Eosin staining. To investigate the
pathological background for the lack of SPIO uptake by
the lesion, immunohistochemical staining using the CD68
marker was performed. CD68 is usually positive in histio-
cytic cells. Immunohistochemical staining revealed that the
cells in EMH were positive for CD68, as in the normal
hepatic parenchyma. However, the degree of staining in
the lesion (weak positive) was much weaker than that in
the normal liver (positive) (Fig. 1G).
DISCUSSION
Contrary to previous reports in which focal intrahepatic
EMH appeared as a heterogeneously enhancing or non-
enhancing mass on contrast-enhanced CT (1 9), this case
exhibited homogeneous and persistent enhancement on
dynamic Gd-enhanced MRI. We are unable to explain
exactly why there was such a discrepancy in the enhance-
ment pattern of the two imaging modalities. However,
earlier studies comparing the MRI and CT hepatic imaging
of focal liver lesions showed that the use of MRI has
several advantages over the use of CT, including greater
sensitivity to intravascular contrast agents (Gd-chelate for
MRI and iodinated agents for CT) (11). Another theoretical
advantage of the use of MRI over the use of CT in terms of
contrast enhancement is that the contrast material is
delivered in a smaller volume over a shorter period in MR
examinations, resulting in a tighter bolus. Considering the
greater sensitivity to the contrast agent and tighter bolus
injection of the contrast agent on MRI than on CT, the
enhancement for a small hepatic lesion might have been
more adequately identified on MRI.
Considering the rarity of the EMH disease entity, it may
not be included in the initial differential lists of hypervas-
cular hepatic lesions. However, given that almost all
patients diagnosed with focal intrahepatic EMH had some
underlying hematological disorder as a predisposing factor
(9), we believe that it merits consideration in the appropri-
ate clinical setting.
Since the early 1980s, the use of SPIO has been applied
to various hepatic and splenic diseases, and many findings
for enhanced lesion characterization have been reported
(12, 13). Due to the RES tissue specificity of SPIO, it
profoundly decreases the signal intensity of the tissues
containing RES cells, such as Kupffer cells, but not that of a
lesion without RES cells, thereby enabling tissue character-
ization. There are two commercially available intravenous
SPIO agents: AMI-25 (Feridex) and SHU 555A (Resovist).
Unlike AMI-25, SHU 555A may be phagocytosed by RES
cells, i.e., macrophages, within the bone marrow as well as
by RES cells in the liver and spleen due to its smaller size
(14, 15). Theoretically, as EMH can possess all marrow
cells, including reticuloendothelial system (RES) precursor
cells, it is expected that intrahepatic EMH would show a
signal drop on a T2*-weighted gradient echo sequence
following SPIO administration. Indeed, in the pathological
specimen of the present case, there were many histiocytic
cells that were considered as precursors of RES cells as
seen by H and E staining. However, contrary to our
expectation, the case did not show any signal drop on post-
SPIO T2*-weighted MR images. There are several possible
explanations for this result. Even though all types of RES
cells, including bone marrow cells may uptake SHU 555A
particles the strength of the affinity of this contrast agent
for each cell is different. SHU 555A has the strongest
affinity to Kupffer cells, followed by RES cells in the spleen
and macrophages in the bone marrow (14, 15). Therefore,
the signal drop induced by SPIO uptake should follow this
tendency, resulting in a weak or even no signal drop of the
intrahepatic EMH. As the ultra-small SPIO (USPIO) agents
can easily cross the capillary wall due to their small size
and prolongation of the blood half-life, it is well known
that USPIO can be taken up by the RES cells of the bone
marrow and lymph nodes (16). If we had used the USPIO
agent as a T2- or T2*-contrast agent, we might have
observed the signal drop within the EMH in our case. A
second possible explanation for the absence of a signal
drop in the lesion on post-SPIO T2*-weighted MR images
may be the short delay time following SPIO administra-
tion. According to previous reports (15), SPIO uptake in
the bone marrow and subsequent decreased relaxation
time of the tissue usually occur within one to 24 hours, or
two hours after SPIO injection. However, in the case of
liver MR imaging using SHU 555A, a 10 minute delay is
optimal in obtaining a signal drop of the liver and spleen.
Therefore, such a short delay time might not be sufficient
to induce a signal drop in the histiocyte-precursor cells of
the EMH.
As this case study is the first to report the SPIO-
enhanced MRI findings of EMH that did not show an
apparent signal drop after SPIO administration, we could
not generalize our result. However, there have been
comparable reports regarding the diagnosis of EMH using
Tc-99m sulfur-colloid scintigraphy (6, 17, 18). In addition,
of the three reported cases of EMH, one case that was
reported by Abbitt et al. (18) showed positive Tc-99m
sulfur-colloid scintigraphy whereas the other two cases
were negative. Considering the similarity of the enhance-
ment mechanism between Tc-99m sulfur-colloid scintigra-
phy and SPIO-enhanced MRI, the SPIO-MRI appearance
of EMH is also expected to be variable. Therefore, further
studies using a large number of cases are warranted to
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investigate the SPIO-enhanced MRI findings of EMH in the
liver.
In the present case, the correct diagnosis was not
originally considered as a focal intrahepatic EMH present-
ing as a homogeneously and persistently enhancing mass
has never been described or included in the differential
diagnosis of hypervascular liver lesions. The differential
diagnosis for hypervascular liver lesions in a non-cirrhotic
liver includes benign tumors such as adenomas, FNH, and
occasionally angiomyolipomas. Malignant hypervascular
hepatic lesions include an HCC and hypervascular
metastasis.
This observation provides further support for the
inclusion of an intrahepatic EMH in the differential diagno-
sis of hypervascular and tumor-like masses without SPIO
(SHU 555A) uptake in patients with hematological
diseases.
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